Nanoparticles for drug delivery in cancer treatment.

By B. Haley, E. Frenkel. Urologic oncology, 2008

803 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tissue-penetrating delivery of compounds and nanoparticles into tumors (2009, positive): “The ability of iRGD to deliver anticancer drugs was investigated by treating mice bearing orthotopic 22Rv1 tumors with iRGDcoated abraxane, a 130 nm nanoparticle consisting of albuminembedded paclitaxel (Haley and Frenkel, 2008; Karmali et al., 2009).”
Liposomes: structure, composition, types, and clinical applications (2022, background): “These variations and unique properties of different NPs could be used to improve the characteristics of traditional therapeutics [8].”
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics (2012, positive): “4.2 Active Targeting Active targeting takes advantage of ligand-receptor, antigen-antibody and other forms of molecular recognition to deliver a particle or drug to a specific location (Haley and Frenkel, 2008).”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “Selective accumulation of nanocarriers and drug then occurs by the EPR effect [32].”
Current trends in the use of liposomes for tumor targeting (2013, background): “The size of the gaps between the endothelial cells lining the tumor capillaries ranges from 100 to 780 nm depending on the cancer type, as opposed to that in a typical normal endothelium of 5–10 nm [7].”